Brokerages remain active with fresh updates across sectors, with several stocks seeing upgrades, reiterations, and target price revisions. Stocks such as L&T, InterGlobe Aviation, CG Power, Coforge, ICICI Bank, and Max Healthcare are among the key names in focus today based on latest brokerage commentary.
Larsen & Toubro: Macquarie reiterates an outperform rating with a target price of ₹4,910, noting that 95% of project sites remain operational despite geopolitical tensions, with only a small portion temporarily stalled. The brokerage adds that the stock has corrected over 22% in the past month, offering attractive valuation comfort at current levels.
InterGlobe Aviation: Goldman Sachs maintains a buy rating with a target price of ₹5,200, highlighting that rising oil prices could reshape the aviation sector dynamics. While near-term earnings may be impacted, the brokerage believes balance sheet strength and cost control will be key differentiators going ahead.
CG Power: UBS reiterates a buy rating and raises the target price to ₹900 from ₹840, citing an inflection point in business with improving domestic demand and strong positioning in the power segment. The brokerage also highlights robust cash position and better export visibility as key positives.
Coforge: UBS initiates coverage with a neutral rating and a target price of ₹1,240, stating that while growth visibility remains strong, concerns around acquisitions and relatively weaker positioning in GenAI balance the risk-reward. In contrast, Motilal Oswal maintains a buy rating with a target price of ₹1,880, citing attractive valuations after sharp correction and limited downside from current levels.
ICICI Bank: Motilal Oswal reiterates a buy call with a target price of ₹1,750, highlighting healthy loan growth, stable margins, and robust asset quality. The brokerage expects operating leverage and steady credit costs to support profitability over the medium term.
Max Healthcare: HSBC upgrades the stock to buy and raises the target price to ₹1,125 from ₹1,060, citing strong growth visibility driven by capacity expansion, improving occupancy, and scale benefits from brownfield additions.
ITC: Morgan Stanley maintains an equal-weight rating with a target price of ₹346, pointing to uncertainty arising from sharp tax increases and their potential impact on volumes and profitability in the near term.
Grasim Industries: Morgan Stanley maintains an overweight rating with a target price of ₹3,865, highlighting strong execution in paints, expansion in high-value cellulose products, and growth potential in chemicals and B2B platforms.
Paytm: Jefferies maintains a buy rating but cuts the target price to ₹1,350 from ₹1,400, citing higher sensitivity to contribution margins. The brokerage, however, remains positive on revenue growth and margin expansion driven by operating leverage.
Sun Pharma and Torrent Pharma: CLSA and Macquarie highlight strong growth potential in the semaglutide segment, with both brokerages indicating that these companies are well positioned to capture incremental demand following sharp price reductions and market expansion.
HDFC Bank: HSBC maintains a buy rating but cuts the target price to ₹990 from ₹1,070, noting that recent management developments could lead to short-term valuation pressure, although core fundamentals remain intact.
Star Health: Jefferies reiterates a buy call with a target price of ₹660, highlighting improving loss ratios, pricing discipline, and strong earnings growth visibility over FY26–28.
Kalyan Jewellers: Motilal Oswal maintains a buy rating with a target price of ₹550, citing resilient domestic demand, improving margins, and continued store expansion despite near-term geopolitical risks in the MENA region.
Premier Energies: DAM Capital reiterates a buy call with a target price of ₹1,295, noting strong technological capabilities, execution strength, and ability to ramp up production faster than peers.
Allied Blenders: Nuvama maintains a buy rating with a target price of ₹670, expecting recovery in volumes, continued premiumisation, and margin expansion supported by favourable raw material trends.
ASK Automotive: CLSA maintains an outperform rating with a target price of ₹640, highlighting strong growth visibility driven by Honda’s capacity expansion and rising content per vehicle, especially in electric two-wheelers.
Disclaimer: The above views are those of respective brokerages and not of the publication. This article is for informational purposes only and does not constitute investment advice.